ePro

Electronic Solutions for Patient-Reported Data
Publié par:
Byrom Bill

Recently, there has been much open debate with the regulators around the use of ePRO in clinical drug submissions. US and European agencies have approved new drugs that have included ePRO data in the submission dossier, but there are many questions around the adoption of the technology that concern the community. Bill Byrom and Brian Tiplady's ePro

juin 2024, env. 294 pages, Anglais
Taylor and Francis
978-1-03-283791-8

Autres titres sur ce thème